Showing 1901-1910 of 5963 results for "".
Join Us for NewDerm LIVE: Welcome from the Chairs
https://practicaldermatology.com/topics/practice-management/join-us-for-newderm-live-welcome-from-the-chairs/18920/Join us September 18-20, 2015 at the W Hollywood, CA for NewDerm Live, the meeting that's focused on you—so you can focus on your future. Program chairs Sabrina Fabi, MD, Peter Lio, MD, and Kavita Mariwalla, MD, talk about the goals of the meeting and explain why they decided to be part of this exciAcne Update: A Review of New Guidelines, Treatment Advances, and Drugs in the Pipeline
https://practicaldermatology.com/topics/general-topics/acne-update-a-review-of-new-guidelines-treatment-advances-and-drugs-in-the-pipeline/18773/Linda Stein Gold, MD talks to DermTube Journal Club Host Joshua Zeichner, MD about the new acne treatment guidelines recently published in the Journal of the American Academy of Dermatology. She discusses the process of developing the guidelines and highlights some of what's new, such as new, limiteNextech: A Specialized, All-in-One Solution
https://practicaldermatology.com/topics/general-topics/nextech-a-specialized-all-in-one-solution/18919/Specialty practices don't need canned solutions to their EMR needs, says dermatologist Saif Sayed of Skincare Specialty Physicians. He left a general EMR for Nextech, which provides "rich capability" to customize the EHR to his practice needs and his approach to patient care. From streamlining officDr. Joel Schlessinger discusses Botox treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-joel-schlessinger-discusses-botox-treatments/19321/Joel Schlessinger, MD takes you through a BOTOX treatment step-by-step, explaining each piece of the process. The video begins with a quick description of BOTOX, Dysport and Xeomin before moving on to show the process of taking pre-treatment photos and performing a consultation. Dr. Schlessinger the- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous
- Medicis Announces Winners of First Annual I Acanya Succeed Scholarship Programhttps://practicaldermatology.com/news/20131007-medicis_announces_winners_of_first_annual_i_acanya_succeed_scholarship_program/2459442/Medics, a division of Valeant Pharmaceuticals North America LLC, recently announced the winners of its first I Acanya Succeed scholarship program, an education-based initiative that provides scholarships to college students who h
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- Biosimilar Update: Dr. Reddy’s Completes Phase I Study of Proposed Tocilizumab Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-dr-reddys-completes-phase-i-study-of-proposed-tocilizumab-biosimilar/2461765/Dr. Reddy’s Laboratories’ tocilizumab biosimilar candidate, DRL_TC, met its primary and secondary endpoints in a Phase I study. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogeni
- Kintor Pharma Completes Enrollment and Dosing in Phase I Clinical Trial of AGA, Acne Drughttps://practicaldermatology.com/news/kintor-pharma-completes-enrollment-and-dosing-in-phase-i-clinical-trial-of-aga-acne-drug/2461404/Kintor Pharmaceutical Limited has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne. Developed through Kintor Pharma's proprietary Proteolysis Targeting Chimera (PROTAC) platfo
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu